Home
Platform
About
Pipeline
News
Careers
More
Dragonfly to Present Preclinical Data on Clinical-Stage DF6215, its Engineered IL-2R alpha-active Agonist, and DF9001, its EGFR-targeting TriNKET®, at SITC
Dragonfly Therapeutics Appoints Dr. Susan Altschuller as Chief Financial Officer
Dragonfly Announces Clinical Collaboration to Evaluate DF9001 in Combination with KEYTRUDA® in Patients with Solid Tumors
Dragonfly has Received Milestone Payment Following Dosing of First Patient in AbbVie Phase 1 Clinical Trial Evaluating DF4101/ABBV-303
Dragonfly Announces Clinical Collaboration Exploring Combinations of Dragonfly's DF1001 HER-2 TriNKET® with Gilead's Trodelvy® in two Cancer Indications
Dragonfly Initiates Phase 1/1b Study of its IL-2 Immunotherapy
One R.I. man’s battle with Stage 4 colon cancer
Dragonfly Therapeutics Announces the Presentation of Phase 1 DF1001 TriNKET® Dose Escalation Results
Dr. Robin Edwards and Dr. David Ferry join Dragonfly's Clinical Leadership Team
Dragonfly Therapeutics Announces the Publication of Preclinical Data
Dragonfly Announces it now owns all rights to its DF6002 novel IL12 cytokine
Dr. Joseph E. Eid joins Dragonfly Therapeutics as President of R&D
Dragonfly Therapeutics Announces Sixth Dragonfly TriNKET Opt-in by Bristol Myers Squibb
Dragonfly Therapeutics Announces First Patient Dosed in Phase 1 Study of its EGFR-targeting TriNKET™
Dragonfly Initiates Phase 2 Study of HER2 Targeting TriNKET™ DF1001
Dragonfly Announces First Patient Dosed in Clinical Trial with Merck Evaluating Solid Tumor Target
Gilead and Dragonfly Announce Strategic Research Collaboration to Develop NK Cell Engagers
Dragonfly Announces Multi-Target Expansion of Research Collaboration with AbbVie
Dragonfly Therapeutics Expands Clinical Leadership Team
Bristol Myers partner comes through on IL-12 effort. Now it's Rupert Vessey's turn at bat